JP2016540811A - Ｎ−アシルピペリジンエーテルトロポミオシン関連キナーゼ阻害剤 - Google Patents
Ｎ−アシルピペリジンエーテルトロポミオシン関連キナーゼ阻害剤 Download PDFInfo
- Publication number
- JP2016540811A JP2016540811A JP2016540686A JP2016540686A JP2016540811A JP 2016540811 A JP2016540811 A JP 2016540811A JP 2016540686 A JP2016540686 A JP 2016540686A JP 2016540686 A JP2016540686 A JP 2016540686A JP 2016540811 A JP2016540811 A JP 2016540811A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- oxy
- mmol
- preparation
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 **(C*(CN(*)CC1)I)C1OC(**C(N=C)=C1)=C1C#N Chemical compound **(C*(CN(*)CC1)I)C1OC(**C(N=C)=C1)=C1C#N 0.000 description 10
- IBRYORODRHGOCR-BDAKNGLRSA-N CC(C)(C)OC(N(CC[C@@H]1OS(C)(=O)=O)C[C@H]1F)=O Chemical compound CC(C)(C)OC(N(CC[C@@H]1OS(C)(=O)=O)C[C@H]1F)=O IBRYORODRHGOCR-BDAKNGLRSA-N 0.000 description 1
- UMQCSFPDISEGOQ-MSOLQXFVSA-N CC(C)(C)OC(N(CC[C@@H]1Oc(ncc(-c2c[n](C(C3)CS3(=O)=O)nc2)c2)c2C(N)=O)C[C@H]1F)=O Chemical compound CC(C)(C)OC(N(CC[C@@H]1Oc(ncc(-c2c[n](C(C3)CS3(=O)=O)nc2)c2)c2C(N)=O)C[C@H]1F)=O UMQCSFPDISEGOQ-MSOLQXFVSA-N 0.000 description 1
- IBRYORODRHGOCR-DTWKUNHWSA-N CC(C)(C)OC(N(CC[C@H]1OS(C)(=O)=O)C[C@@H]1F)=O Chemical compound CC(C)(C)OC(N(CC[C@H]1OS(C)(=O)=O)C[C@@H]1F)=O IBRYORODRHGOCR-DTWKUNHWSA-N 0.000 description 1
- YLTJZCYZECLGGN-JGPRNRPPSA-N CC(C)(C)OC(N([C@H](CC1)C2)[C@@H]1C[C@@H]2OS(C)(=O)=O)=O Chemical compound CC(C)(C)OC(N([C@H](CC1)C2)[C@@H]1C[C@@H]2OS(C)(=O)=O)=O YLTJZCYZECLGGN-JGPRNRPPSA-N 0.000 description 1
- GCHUQHKHUFMWDH-UHFFFAOYSA-N CC(C)(C[n]1ncc(B2OC(C)(C)C(C)(C)O2)c1)O Chemical compound CC(C)(C[n]1ncc(B2OC(C)(C)C(C)(C)O2)c1)O GCHUQHKHUFMWDH-UHFFFAOYSA-N 0.000 description 1
- KKVXLUZVSZTIQJ-ZETCQYMHSA-N CC1(C)O[C@@H](CCOS(C)(=O)=O)CO1 Chemical compound CC1(C)O[C@@H](CCOS(C)(=O)=O)CO1 KKVXLUZVSZTIQJ-ZETCQYMHSA-N 0.000 description 1
- NPVICWUXFYMJPD-VIFPVBQESA-N CC1(C)O[C@@H](C[n]2nc(C)c(Br)c2C)CO1 Chemical compound CC1(C)O[C@@H](C[n]2nc(C)c(Br)c2C)CO1 NPVICWUXFYMJPD-VIFPVBQESA-N 0.000 description 1
- VPIUFXPRYQZGEY-LEWJYISDSA-N CCOC(c1c[n](-c(cn2)cc(C(N)=O)c2O[C@H](CCN(C2)C(Cc(cc3)ccc3OC(F)(F)F)=O)[C@H]2F)nc1)=O Chemical compound CCOC(c1c[n](-c(cn2)cc(C(N)=O)c2O[C@H](CCN(C2)C(Cc(cc3)ccc3OC(F)(F)F)=O)[C@H]2F)nc1)=O VPIUFXPRYQZGEY-LEWJYISDSA-N 0.000 description 1
- CSIQTIMSSAAFFT-UHFFFAOYSA-N COC(c(cc(cn1)C#C)c1OCc1ccccc1)=O Chemical compound COC(c(cc(cn1)C#C)c1OCc1ccccc1)=O CSIQTIMSSAAFFT-UHFFFAOYSA-N 0.000 description 1
- FIOPLNQLVKBWJA-UHFFFAOYSA-N COc1ccc(C(c2ccccc2)(c2ccccc2)[n]2c(Br)cnc2)cc1 Chemical compound COc1ccc(C(c2ccccc2)(c2ccccc2)[n]2c(Br)cnc2)cc1 FIOPLNQLVKBWJA-UHFFFAOYSA-N 0.000 description 1
- RYEGIHSVGLGLFF-UHFFFAOYSA-N C[n](nc1)nc1-c(cn1)cc(C(N)=O)c1O Chemical compound C[n](nc1)nc1-c(cn1)cc(C(N)=O)c1O RYEGIHSVGLGLFF-UHFFFAOYSA-N 0.000 description 1
- HGIHTFYDNBTGJE-JFGZAKSSSA-N C[n]1c(-c(cn2)cc(C(N)=O)c2O[C@H](CCN(C2)C(Cc(cc3)ccc3OC3CC3)=O)C2F)cnc1 Chemical compound C[n]1c(-c(cn2)cc(C(N)=O)c2O[C@H](CCN(C2)C(Cc(cc3)ccc3OC3CC3)=O)C2F)cnc1 HGIHTFYDNBTGJE-JFGZAKSSSA-N 0.000 description 1
- GRYMZUBCDUMPEW-UHFFFAOYSA-N C[n]1cnc(-c(cc2)cc(C(N)=O)c2OCc2ccccc2)c1 Chemical compound C[n]1cnc(-c(cc2)cc(C(N)=O)c2OCc2ccccc2)c1 GRYMZUBCDUMPEW-UHFFFAOYSA-N 0.000 description 1
- XJIIVPVOGYFVME-UHFFFAOYSA-N C[n]1cnc(-c(cn2)cc(C(N)=O)c2OC(CCN(C2)C(Cc(cc3)ccc3OC(F)(F)F)=O)C2F)c1 Chemical compound C[n]1cnc(-c(cn2)cc(C(N)=O)c2OC(CCN(C2)C(Cc(cc3)ccc3OC(F)(F)F)=O)C2F)c1 XJIIVPVOGYFVME-UHFFFAOYSA-N 0.000 description 1
- FIYQZFVPIIRYTJ-UXHICEINSA-N C[n]1ncc(-c(cn2)cc(C(N)=O)c2O[C@@H](CCN(C2)C(Cc(cc3)ccc3OC(F)(F)F)=O)[C@@H]2F)c1 Chemical compound C[n]1ncc(-c(cn2)cc(C(N)=O)c2O[C@@H](CCN(C2)C(Cc(cc3)ccc3OC(F)(F)F)=O)[C@@H]2F)c1 FIYQZFVPIIRYTJ-UXHICEINSA-N 0.000 description 1
- IMCOCNSGBFMPOS-PKOBYXMFSA-N C[n]1nnc(-c(cn2)cc(C(N)=O)c2O[C@H](CCN(C2)C(Cc(cc3)ccc3OC(F)(F)F)=O)[C@H]2F)c1 Chemical compound C[n]1nnc(-c(cn2)cc(C(N)=O)c2O[C@H](CCN(C2)C(Cc(cc3)ccc3OC(F)(F)F)=O)[C@H]2F)c1 IMCOCNSGBFMPOS-PKOBYXMFSA-N 0.000 description 1
- INSBUPMKSLSIDB-UHFFFAOYSA-N Cc(c(Br)c1)nc(O)c1C(N)=O Chemical compound Cc(c(Br)c1)nc(O)c1C(N)=O INSBUPMKSLSIDB-UHFFFAOYSA-N 0.000 description 1
- ZFCYBCCSFMDXTK-VQTJNVASSA-N Cc(nc1)c[n]1-c(cn1)cc(C(N)=O)c1O[C@H](CCN(C1)C(Cc(cc2)ccc2OC(F)(F)F)=O)[C@H]1F Chemical compound Cc(nc1)c[n]1-c(cn1)cc(C(N)=O)c1O[C@H](CCN(C1)C(Cc(cc2)ccc2OC(F)(F)F)=O)[C@H]1F ZFCYBCCSFMDXTK-VQTJNVASSA-N 0.000 description 1
- BGSYILXGRSFJGC-LJQANCHMSA-N NC(c(cc(cc1)-c2c[n](C[C@H](CO)O)cn2)c1OC(CC1)CCN1C(Cc(cc1)ccc1OC(F)(F)F)=O)=O Chemical compound NC(c(cc(cc1)-c2c[n](C[C@H](CO)O)cn2)c1OC(CC1)CCN1C(Cc(cc1)ccc1OC(F)(F)F)=O)=O BGSYILXGRSFJGC-LJQANCHMSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361918783P | 2013-12-20 | 2013-12-20 | |
| US61/918,783 | 2013-12-20 | ||
| PCT/IB2014/066707 WO2015092610A1 (en) | 2013-12-20 | 2014-12-08 | N-acylpiperidine ether tropomyosin-related kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016540811A true JP2016540811A (ja) | 2016-12-28 |
| JP2016540811A5 JP2016540811A5 (enExample) | 2017-12-28 |
Family
ID=52440728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016540686A Withdrawn JP2016540811A (ja) | 2013-12-20 | 2014-12-08 | Ｎ−アシルピペリジンエーテルトロポミオシン関連キナーゼ阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20170305857A1 (enExample) |
| EP (1) | EP3083602A1 (enExample) |
| JP (1) | JP2016540811A (enExample) |
| CA (1) | CA2934010A1 (enExample) |
| WO (1) | WO2015092610A1 (enExample) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020526547A (ja) * | 2017-07-12 | 2020-08-31 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 心不全の治療のためのｒｏｃｋの５員アミノヘテロ環および５，６−または６，６員二環式アミノヘテロ環の阻害剤 |
| JP2021529807A (ja) * | 2018-07-05 | 2021-11-04 | アイカーン スクール オブ メディスン アット マウント シナイ | タンパク質チロシンキナーゼ６（ｐｔｋ６）分解／破壊化合物および使用方法 |
| US12103924B2 (en) | 2020-06-01 | 2024-10-01 | Icahn School Of Medicine At Mount Sinai | Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use |
| US12110295B2 (en) | 2018-06-21 | 2024-10-08 | Icahn School Of Medicine At Mount Sinai | WD40 repeat domain protein 5 (WDR5) degradation/disruption compounds and methods of use |
| US12274697B2 (en) | 2016-10-28 | 2025-04-15 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating EZH2-mediated cancer |
| US12465648B2 (en) | 2019-05-06 | 2025-11-11 | Icahn School Of Medicine At Mount Sinai | Heterobifunctional compounds as degraders of HPK1 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016009296A1 (en) * | 2014-07-16 | 2016-01-21 | Pfizer Inc. | N-acylpiperidine ether tropomyosin-related kinase inhibitors |
| WO2016020784A1 (en) * | 2014-08-05 | 2016-02-11 | Pfizer Inc. | N-acylpyrrolidine ether tropomyosin-related kinase inhibitors |
| CN109970631A (zh) * | 2019-03-26 | 2019-07-05 | 上海吉奉生物科技有限公司 | 一种5-碘-2-吡啶乙酸的合成方法 |
| CN116396298A (zh) * | 2023-06-06 | 2023-07-07 | 四川维亚本苑生物科技有限公司 | CDK Ligand-1的中间体XII及CDK Ligand-1的制备方法 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3958002A (en) | 1972-06-20 | 1976-05-18 | Pierre Fabre S.A. | Medicaments having psychotropic properties (antitussives) |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| UA80171C2 (en) | 2002-12-19 | 2007-08-27 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives |
| EP1636207A1 (en) * | 2003-06-12 | 2006-03-22 | Novo Nordisk A/S | Substituted piperidine carbamates for use as inhibitors of hormone sensitive lipase |
| US7417063B2 (en) | 2004-04-13 | 2008-08-26 | Bristol-Myers Squibb Company | Bicyclic heterocycles useful as serine protease inhibitors |
| JP4842929B2 (ja) | 2004-05-27 | 2011-12-21 | ファイザー・プロダクツ・インク | 癌治療に有用なピロロピリミジン誘導体 |
| US20070275968A1 (en) | 2004-09-07 | 2007-11-29 | Hitoshi Kurata | Substituted Biphenyl Derivative |
| US8071768B2 (en) * | 2005-06-10 | 2011-12-06 | Janssen Pharmaceutica, N.V. | Alkylquinoline and alkylquinazoline kinase modulators |
| US7405302B2 (en) | 2005-10-11 | 2008-07-29 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| GB0526107D0 (en) | 2005-12-22 | 2006-02-01 | Angeletti P Ist Richerche Bio | Therapeutic Compounds |
| RU2323058C1 (ru) | 2006-07-12 | 2008-04-27 | ООО Научно-внедренческий центр "Машины и оборудование для энергетики" | Способ формирования наружной резьбы на концевом участке трубной заготовки |
| JPWO2008023720A1 (ja) * | 2006-08-23 | 2010-01-14 | アステラス製薬株式会社 | ウレア化合物又はその塩 |
| RU2009122670A (ru) | 2006-12-21 | 2011-01-27 | Плекссикон, Инк. (Us) | Соединения и способы для модуляции киназ и показания к их применению |
| CL2008000835A1 (es) | 2007-03-23 | 2008-10-03 | Icagen Inc Pfizer Ltd | Compuestos derivados de sulfonamidas, inhibidores de los canales de calcio; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, sindrome de intestino irritable, enfermedad de crohn, taquiarritm |
| JP2010533729A (ja) | 2007-07-17 | 2010-10-28 | プレキシコン，インコーポレーテッド | キナーゼ調節のための化合物と方法、及びそのための適応 |
| US8158636B2 (en) | 2008-05-19 | 2012-04-17 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| PE20091846A1 (es) | 2008-05-19 | 2009-12-16 | Plexxikon Inc | DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS |
| US8110576B2 (en) | 2008-06-10 | 2012-02-07 | Plexxikon Inc. | Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications |
| CN104530052A (zh) | 2008-06-10 | 2015-04-22 | 普莱希科公司 | 用于激酶调节的5h-吡咯[2,3-b]吡嗪衍生物和其适应症 |
| CA2747419C (en) | 2009-01-12 | 2014-07-08 | Icagen, Inc. | Sulfonamide derivatives |
| CN102438991B (zh) | 2009-04-29 | 2015-08-26 | 兴和株式会社 | 具有杂环连接基的甲醇化合物 |
| WO2011021645A1 (ja) * | 2009-08-19 | 2011-02-24 | 大日本住友製薬株式会社 | ２環性ウレア誘導体、またはその薬学的に許容される塩 |
| TWI510487B (zh) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | 用於激酶調節的化合物和方法及其適應症 |
| EP2694509B1 (en) | 2011-04-05 | 2016-05-18 | Pfizer Limited | Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of tropomyosin-related kinases |
| NZ618795A (en) | 2011-05-13 | 2015-07-31 | Array Biopharma Inc | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors |
| JP2014520879A (ja) | 2011-07-15 | 2014-08-25 | ファイザー・インク | Ｇｐｒ１１９調節因子 |
| KR20140105508A (ko) | 2011-12-12 | 2014-09-01 | 닥터 레디스 레보러터리즈 리미티드 | 트로포미오신 수용체 키나제(Trk) 억제제인 치환된 피라졸로[1,5-a]피리딘 |
| ES2605388T3 (es) | 2012-04-26 | 2017-03-14 | Ono Pharmaceutical Co., Ltd. | Compuesto inhibidor de Trk |
-
2014
- 2014-12-08 JP JP2016540686A patent/JP2016540811A/ja not_active Withdrawn
- 2014-12-08 US US15/101,476 patent/US20170305857A1/en not_active Abandoned
- 2014-12-08 CA CA2934010A patent/CA2934010A1/en not_active Abandoned
- 2014-12-08 WO PCT/IB2014/066707 patent/WO2015092610A1/en not_active Ceased
- 2014-12-08 EP EP14833379.2A patent/EP3083602A1/en not_active Withdrawn
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12274697B2 (en) | 2016-10-28 | 2025-04-15 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating EZH2-mediated cancer |
| JP2020526547A (ja) * | 2017-07-12 | 2020-08-31 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 心不全の治療のためのｒｏｃｋの５員アミノヘテロ環および５，６−または６，６員二環式アミノヘテロ環の阻害剤 |
| JP7234201B2 (ja) | 2017-07-12 | 2023-03-07 | ブリストル－マイヤーズ スクイブ カンパニー | 心不全の治療のためのｒｏｃｋの５員アミノヘテロ環および５，６－または６，６員二環式アミノヘテロ環の阻害剤 |
| US12110295B2 (en) | 2018-06-21 | 2024-10-08 | Icahn School Of Medicine At Mount Sinai | WD40 repeat domain protein 5 (WDR5) degradation/disruption compounds and methods of use |
| JP2021529807A (ja) * | 2018-07-05 | 2021-11-04 | アイカーン スクール オブ メディスン アット マウント シナイ | タンパク質チロシンキナーゼ６（ｐｔｋ６）分解／破壊化合物および使用方法 |
| US12678507B2 (en) | 2018-07-05 | 2026-07-14 | Icahn School Of Medicine At Mount Sinai | Protein tyrosine kinase 6 (PTK6) degradation / disruption compounds and methods of use |
| US12465648B2 (en) | 2019-05-06 | 2025-11-11 | Icahn School Of Medicine At Mount Sinai | Heterobifunctional compounds as degraders of HPK1 |
| US12103924B2 (en) | 2020-06-01 | 2024-10-01 | Icahn School Of Medicine At Mount Sinai | Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3083602A1 (en) | 2016-10-26 |
| WO2015092610A1 (en) | 2015-06-25 |
| US20170305857A1 (en) | 2017-10-26 |
| CA2934010A1 (en) | 2015-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102924294B1 (ko) | 아졸-융합된 피리다진-3(2h)-온 유도체 | |
| JP5595616B2 (ja) | トロポミオシン関連キナーゼ阻害薬としてのピロロ［２，３−ｄ］ピリミジン誘導体 | |
| ES2548228T3 (es) | Derivados de bencimidazol e imidazopiridina como moduladores de canal de sodio | |
| AU2014291711B2 (en) | Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core | |
| EP2909212B1 (en) | Substituted 1,4-dihydropyrazolo[4,3-b]indoles | |
| US9328096B2 (en) | Tropomyosin-related kinase inhibitors | |
| US20170305857A1 (en) | N-acylpiperidine ether tropomyosin-related kinase inhibitors | |
| WO2020223255A1 (en) | 3-amino-4h-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of mrgx2 | |
| US20170197939A1 (en) | Tropomyosin-Related Kinase Inhibitors Containing Both A 1H-Pyrazole And A Pyrimidine Moiety | |
| EP3697410B1 (en) | Benzimidazole derivatives and their uses | |
| US20260053834A1 (en) | Covalent modifiers of akt1 and uses thereof | |
| US9163021B2 (en) | Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors | |
| JP2015531394A (ja) | ピロロ［２，３−ｄ］ピリミジントロポミオシン関連キナーゼ阻害剤 | |
| JP2015531393A (ja) | トロポミオシン関連キナーゼ阻害剤 | |
| HK40076219B (en) | Azole-fused pyridazin-3(2h)-one derivatives | |
| HK40076219A (en) | Azole-fused pyridazin-3(2h)-one derivatives | |
| TW201617334A (zh) | 可作為原肌球蛋白相關之激酶抑制劑之ｎ－醯基吡咯啶醚 | |
| EA053259B1 (ru) | Конденсированные с азолом производные пиридазин-3(2н)-она |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171114 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171114 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20171121 |